Optimizing Ancillary Therapies With Immune Checkpoint Inhibitors for Solid Tumors (OAT ICI)

NCT07661459 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

98

Enrollment

OTHER

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: Asprin
DRUG: Loratadine
BEHAVIORAL: Acetaminophen Avoidance
BEHAVIORAL: THC Avoidance

Sponsor

Val Adams